Abstract
Greater trochanter pain syndrome (GTPS) occurs in a large group of patients. This problem can affect patients of any age and is associated with a sedentary, overloading, and non-ergonomic lifestyle/work with a concomitant lack of regular physical activity. The literature to date describes the effectiveness of various therapies. Glucocorticosteroid injections and physical therapy are used. One of the new methods is injection collagen therapy using collagen type I (COL-I), a protein of porcine origin, which aims, among other things, to regenerate inflammation-changed tendon. Various repair mechanisms are activated, including the induction and proliferation of fibroblasts, as well as their migration to the pathological site. This is followed by stimulation and synthesis of COL-I, secretion, and maturation. Ultimately, a regenerative effect is achieved. This article aims to discuss the role of COL-I in the injectable treatment of GTPS as a new therapeutic approach.